Aberrant regulation of the GSK‐3β/NRF2 axis unveils a novel therapy for adrenoleukodystrophy
Year: 2018
Type: article
Abstract: The nuclear factor erythroid 2‐like 2 (NRF2) is the master regulator of endogenous antioxidant responses. Oxidative damage is a shared and early‐appearing feature in X‐linked adrenoleukodystrophy (X‐ALD) patients and the mouse model (Abcd1 null mouse). This rare neurometabolic disease is caused by the loss of function of the peroxisomal transporter ABCD1, leading to an accumulation of very long‐chain fatty acids and the induction of reactive oxygen species of mitochondrial origin. Here, we identify an impaired NRF2 response caused by aberrant activity of GSK‐3β. We find that GSK‐3β inhibitors can significantly reactivate the blunted NRF2 response in patients’ fibroblasts. In the mouse models (Abcd1− and Abcd1−/Abcd2−/− mice), oral administration of dimethyl fumarate (DMF/BG12/Tecfidera), an NRF2 activator in use for multiple sclerosis, normalized (i) mitochondrial depletion, (ii) bioenergetic failure, (iii) oxidative damage, and (iv) inflammation, highlighting an intricate cross‐talk governing energetic and redox homeostasis in X‐ALD. Importantly, DMF halted axonal degeneration and locomotor disability suggesting that therapies activating NRF2 hold therapeutic potential for X‐ALD and other axonopathies with impaired GSK‐3β/NRF2 axis. This study reports an aberrant, chronic inhibition of the endogenous antioxidant response driven by NRF2 in adrenoleukodystrophy. Reactivating this pathway in the mouse model with dimethyl fumarate unveils a promising therapeutic option. This study reports an aberrant, chronic inhibition of the endogenous antioxidant response driven by NRF2 in adrenoleukodystrophy. Reactivating this pathway in the mouse model with dimethyl fumarate unveils a promising therapeutic option.
Source: EMBO Molecular Medicine
Institutions: Instituto de Salud Carlos III, Institut d'Investigació Biomédica de Bellvitge, Centre for Biomedical Network Research on Rare Diseases, Weill Cornell Medicine, Centre National de la Recherche Scientifique, Inserm, Sorbonne Université, Institut du Cerveau, Université Pierre-et-Marie-Curie, Universitat de Lleida, Bellvitge University Hospital, Biomedical Research Networking Center on Neurodegenerative Diseases, Universitat de Barcelona, Institució Catalana de Recerca i Estudis Avançats
Language: English
Subfield: Clinical Biochemistry
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $7,990
Awards: G1681041121, G3234761582, G3798823019, G4034559871, G4369012136, G4680071626, Therapeutic challenge in Leukodystrophies: Translational and ethical research towards clinical trials, G5083560972, G512892266, G5178817491, G5675042963, G5802927044, G5928831250, G5983582375, G621654008, G6350668883, G8003096289, G8170558114, G8290874678
OpenAlex ID: W2861844602
